MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/0148607115626921

Медицинская библиотека · JPEN. Journal of parenteral and enteral nutrition · 2016

Preventing the Progression of Intestinal Failure-Associated Liver Disease in Infants Using a Composite Lipid Emulsion: A Pilot Randomized Controlled Trial of SMOFlipid.

Diamond Ivan R, Grant Robert C, Pencharz Paul B, de Silva Nicole, Feldman Brian M, Fitzgerald Peter, Sigalet David, Dicken Bryan, Turner Justine, Marchand Valerie, Ling Simon C, Moore Aideen M, Avitzur Yaron, Wales Paul W

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

To examine whether SMOFlipid prevents progression of intestinal failure-associated liver disease (IFALD) in parenteral nutrition (PN)-dependent infants with early IFALD (conjugated bilirubin 17-50 µmol/L, 1-3 mg/dL).

STUDY

DESIGN

Pilot multicenter blinded randomized controlled trial comparing SMOFlipid with Intralipid. Patients received the trial lipid for up to 12 weeks, unless they achieved full enteral tolerance sooner. The primary clinical outcome was the serum conjugated bilirubin.

RESULTS

Twenty-four infants (mean age, 6 weeks) participated in the trial (13 Intralipid and 11 SMOFlipid). At the time of trial enrollment, patients in both groups were receiving 90% of their calories by PN. Mean duration on trial was 8 weeks and did not differ according to treatment ( P = .99). At trial conclusion, patients who received SMOFlipid had a lower conjugated bilirubin than those who received Intralipid (mean difference, -59 µmol/L; P = .03). Patients receiving SMOFlipid were also more likely to have a decrease in serum conjugated bilirubin to 0 µmol/L than those in the Intralipid group over the entire observation period (hazard ratio, 10.6; 95%; P = .03). The time to achievement of full enteral tolerance did not differ statistically (hazard ratio, 1.3; P = .59) between the groups. There was no significant difference in safety outcomes between the groups.

CONCLUSIONS

Compared with Intralipid, SMOFlipid reduces the risk of progressive IFALD in children with intestinal failure. This trial was registered at clinicaltrials.gov as NCT00793195.

Для цитирования: Diamond Ivan R, Grant Robert C, Pencharz Paul B, de Silva Nicole, Feldman Brian M, Fitzgerald Peter, Sigalet David, Dicken Bryan, Turner Justine, Marchand Valerie, Ling Simon C, Moore Aideen M, Avitzur Yaron, Wales Paul W. Preventing the Progression of Intestinal Failure-Associated Liver Disease in Infants Using a Composite Lipid Emulsion: A Pilot Randomized Controlled Trial of SMOFlipid.. JPEN. Journal of parenteral and enteral nutrition. 2016. DOI: 10.1177/0148607115626921.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.